Star Therapeutics: $90 Million Closed To Interrogate Areas Of Novel Biology To Develop Life-Changing Therapies
By Dan Anderson ● Sep 5, 2023
Star Therapeutics - a biotechnology company interrogating novel biology to develop life-changing therapies - recently announced the closing of an oversubscribed $90 million Series C financing to continue the growth of its first-in-class antibody therapies and portfolio companies. The funding was led by Sofinnova Investments and included new investors Qatar Investment Authority (QIA), Catalio Capital Management, Agent Capital, Soleus Capital, and NYBC Ventures, as well as participation by all existing investors, including Westlake Village BioPartners, OrbiMed, Redmile Group, RA Capital Management, New Leaf Venture Partners, Cormorant Asset Management, and Cowen Healthcare Investments. Including this Series C funding round, Star Therapeutics has raised over $190 million since its inception to create numerous portfolio companies.